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Abstract
Background: Cerebral ischemia results in a rapid increase in contractile cerebrovascular receptors, such as the 5-
hydroxytryptamine type 1B (5-HT1B), angiotensin II type 1 (AT1), and endothelin type B (ETB) receptors, in the vessel
walls within the ischemic region, which further impairs local blood flow and aggravates tissue damage. This
receptor upregulation occurs via activation of the mitogen-activated protein kinase pathway. We therefore
hypothesized an important role for B-Raf, the first signaling molecule in the pathway. To test our hypothesis,
human cerebral arteries were incubated at 37°C for 48 h in the absence or presence of a B-Raf inhibitor: SB-386023
or SB-590885. Contractile properties were evaluated in a myograph and protein expression of the individual
receptors and activated phosphorylated B-Raf (p-B-Raf) was evaluated immunohistochemically.
Results: 5-HT1B,A T 1, and ETB receptor-mediated contractions were significantly reduced by application of SB-
590885, and to a smaller extent by SB-386023. A marked reduction in AT1 receptor immunoreactivity was observed
after treatment with SB-590885. Treatment with SB-590885 and SB-386023 diminished the culture-induced increase
of p-B-Raf immunoreactivity.
Conclusions: B-Raf signaling has a key function in the altered expression of vascular contractile receptors observed
after organ culture. Therefore, specific targeting of B-Raf might be a novel approach to reduce tissue damage after
cerebral ischemia by preventing the previously observed upregulation of contractile receptors in smooth muscle
cells.
Background
Although cerebral ischemia is a leading cause of mor-
bidity and mortality worldwide, few therapeutic
advances appear to be of value in the clinic [1]. We
have observed an inherent tendency of the vasculature
to undergo phenotypic changes as a response to cerebral
ischemia [2]. Therefore, the cerebral vessels show tran-
scriptional upregulation of the vasoconstrictive G-pro-
tein coupled receptors (GPCRs) 5-hydroxytryptamine
type 1B (5-HT1B), angiotensin II type 1 (AT1)a n d
endothelin type B (ETB) after experimental subarachnoid
hemorrhage (SAH) or after focal ischemic stroke [3,4].
Identical receptor upregulation has been observed in
patients that died of stroke [5]. In both types of
experimental stroke, the receptor upregulation is
mediated via the mitogen-activated protein kinase path-
way MEK/ERK1/2 [6,7]. A similar type of receptor upre-
gulation can be achieved experimentally by incubating
isolated arteries in serum-free culture medium at 37°C
for 12 to 48 h [8].
The first signaling molecule in the MEK/ERK1/2 path-
way, Raf, is a serine/threonine kinase existing in three
different isoforms (A-, B-, and C-Raf) with a common
activator, Ras, and a single known common substrate,
MEK. Even though MEK is the common substrate,
experiments on Raf knock-out mice show isoform-speci-
fic functions for A-, B-, and C-Raf [9]. B-Raf is the only
isoform that is strongly activated by Ras alone [10] and
the most active isoform when it comes to phosphorylat-
ing MEK in vitro [11]. We therefore designed this study
to examine the role of the B-Raf isoform in inducing the
observed GPCR alterations seen after cerebral ischemia.
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were used in this study, SB-386023 [12] and SB-590885
[13]. The inhibitors are both small ATP competitive
inhibitors with high selectivity for B-Raf when tested
against a panel of related protein kinases, but are differ-
ent in that SB-590885 has a higher affinity for B-Raf.
We show that culturing human cerebral arteries in the
presence of B-Raf inhibitors strongly attenuates 5-HT1B,
AT1, and ETB receptor-mediated contractions compared
with arteries cultured with vehicle alone. The receptor
proteins were evaluated with immunofluorescence and a
marked reduction in AT1 receptor immunofluorescence
was observed after treatment with SB-590885. Addition-
ally, the observed increase in phosphorylated B-Raf (p-
B-Raf) immunoreactivity after incubation was dimin-
ished after treatment with the B-Raf inhibitors.
Results
In vitro pharmacology
Initially, the vessel segments were normalized and
stretched to 90% of the internal circumference that a
fully relaxed vessel under a transmural pressure of 100
mm Hg would have. The mean normalized internal cir-
cumference and standard deviation was 725 ± 297 μm. K
+-induced contractions did not differ significantly among
the three groups; vehicle, SB-386023, and SB-590885
data confirmed that all groups responded similarly to K
+,
excluding the possibility that the B-Raf inhibitors had an
effect on the viability of the vessels. Emax and pEC50
values for each group are presented in Table 1.
Contractile responses to 5-carboxamidotryptamine
5-HT1B receptor-mediated contraction was studied using
cumulative application of 5-carboxamidotryptamine (5-
CT). Vessel segments treated with SB-386023 or SB-
590885 both showed attenuated contractile responses to
5-CT and gave rise to reduced Emax values compared
with vehicle-treated vessels (Figure 1A). The inhibitory
effect was significant for vessels treated with SB-590885,
Emax 11.75 ± 3.43% compared with 39.20 ± 12.09% for
the vehicle group (P < 0.05, Table 1).
Contractile responses to angiotensin II
Application of angiotensin II (Ang II) induced a concen-
tration-dependent contractile response at lower concen-
trations (10
-12 -3 · 1 0
-9 M) and dilatation at higher
concentrations (10
-8 -3 · 1 0
-6 M, data not shown). The
maximum contraction was attenuated after treatment
with SB-590885 (11.56 ± 2.72%, P < 0.001) and SB-
386023 (26.20 ± 4.37%, not significant) compared with
46.43 ± 6.78% for the control vessels treated with vehi-
cle (Figure 1B, Table 1).
Contractile responses to endothelin-1
Endothelin-1 (ET-1) gave rise to a biphasic concentra-
tion-dependent response indicating the presence of both
ETA (low affinity) and ETB (high affinity) receptors in a
manner previously characterized in detail [14]. The
high-affinity phase corresponding to ETB receptor-
mediated contraction was significantly decreased in the
presence of SB-590885 (7.44 ± 2.44%, P < 0.05) while
SB-386023 did not have a significant effect (25.60 ±
7.40%) compared with vehicle 36.71 ± 12.09% (Figure
1C, Table 1). ETA receptor-mediated contractions (low-
affinity phase) were not significantly altered by the
application of either inhibitor (Figure 1C).
Immunohistochemistry
Hematoxylin-eosin staining was performed on all speci-
mens. No morphological differences were observed in
Table 1 Contractile responses to 5-CT, Ang II, and ET-1
Sigmoidal curve Biphasic curve
nK
+ (mN) Emax (%) pEC50 Emax(1) (%) Emax(2) (%) pEC50(1) pEC50(2)
5-CT
Vehicle 5 6.87 ± 1.07 39.20 ± 12.09 6.92 ± 0.40
SB-386023 6 7.42 ± 1.10 25.13 ± 4.75 7.28 ± 0.31
SB-590885 6 5.45 ± 1.16 11.75 ± 3.43* 6.65 ± 0.25
Ang II
Vehicle 6 7.16 ± 0.92 46.43 ± 6.78 10.11 ± 0.25
SB-386023 7 7.08 ± 0.95 26.20 ± 4.37 10.15 ± 0.23
SB-590885 7 5.88 ± 1.12 11.56 ± 2.72*** 9.45 ± 0.96
ET-1
Vehicle 6 7.16 ± 0.92 36.71 ± 12.09 128.40 ± 6.91 11.74 ± 0.20 9.17 ± 0.18
SB-386023 7 7.08 ± 0.95 25.60 ± 7.40 132.20 ± 8.46 11.73 ± 0.16 8.96 ± 0.20
SB-590885 7 5.88 ± 1.12 7.44 ± 2.44* 147.4 ± 11.04 11.37 ± 0.20 9.07 ± 0.08
Responses were characterized by Emax values, expressed as percent of 63.5 mM K
+-induced contraction, and pEC50 values. Values are represented as mean ± s.e.
m., with n representing the number of patients. Statistical analyses were performed using the non-parametric Kruskal-Wallis test and Dunn´s multiple comparison
test. *P < 0.05, ***P < 0.001 compared with vehicle. 5-CT - 5-carboxamidotryptamine, Ang II - Angiotensin II, ET-1 - Endothelin-1.
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pressed areas from the wires in the in vitro pharmacol-
ogy experiments (Figure 2). Therefore, these areas were
not used for any kind of evaluation or analysis in the
immunohistochemical experiments.
Expression of G-protein coupled receptors
Protein expression of individual receptors was evaluated
with immunofluorescence using antibodies against the
5-HT1B,A T 1 (Figure 3A, B), AT2,E T A (Figure 3C), and
ETB receptors. In addition, double immunostaining was
performed with 5-HT1B,A T 1,a n dE T B receptors
together with actin (smooth muscle cell layer) to deter-
mine the localization of the receptors. Double staining
revealed that all three receptors were found in the
smooth muscle cell layer (AT1, Figure 3A).
Fluorescence intensity measurements were performed
on all receptor stainings. Because of inter-individual dif-
ferences and differences in pre-treatment and in vessel
size, we did not see a close correlation between immu-
nostaining and the in vitro experiments. However, a
marked increase in AT1 receptor immunofluorescence
was observed in organ cultured vessels treated with
vehicle compared with fresh,n o n - c u l t u r e dv e s s e l s .T h e
immunofluorescence was reduced in vessels treated with
SB-590885, and to a smaller extent after treatment with
SB-386023 (Figure 3B), compared with vehicle. No sig-
nificant differences in 5-HT1B,A T 2,E T B,a n dE T A (Fig-
ure 3C) receptor immunoreactivity were detected.
Expression of phosphorylated B-Raf
The protein expression of activated p-B-Raf was evalu-
ated with immunofluorescence. As in the receptor
immunofluorescence experiments, inter-individual and
segmental differences were observed. Nevertheless, an
increase in p-B-Raf immunoreactivity was observed in
cultured brain vessels compared with fresh non-cultured
vessels. In addition, immunofluorescence intensity was
clearly reduced in vessels treated with SB-590885 or SB-
386023 (Figure 4).
Discussion
The present study demonstrates for the first time that
upregulation of the contractile receptors 5-HT1B,A T 1,
and ETB in human cerebral arteries is mediated by B-
Raf signaling. These receptor subtypes have been char-
acterized in human cerebral arteries in detail in previous
studies [15-17]. In human ischemic stroke, we have
observed enhanced levels of protein and mRNA of 5-
HT1B,A T 1,a n dE T B receptors in middle cerebral artery
smooth muscle cells [5]. Presently, the co-incubation of
Figure 1 Contractile responses to 5-carboxamidotryptamine (5-
CT) (A), angiotensin II (Ang II) (B), and endothelin-1 (ET-1) (C)
in human cerebral arteries. Effect of organ culture in the presence
of vehicle (n = 5 to 6) and in the presence of SB-590885 (n = 6 to
7) and SB-386023 (n = 6 to 7) are illustrated. The receptor-mediated
contractions are clearly reduced by SB-590885. Data are expressed
as mean ± s.e.m. ET-1 biphasic concentration-response curve: high-
affinity phase refers to the endothelin type B (ETB) receptor-
mediated contraction; low-affinity phase refers to the endothelin
type A (ETA) receptor-mediated contraction. Statistical analyses are
shown for the Emax values where *P < 0.05 and ***P < 0.001
compared with vehicle. Emax values and pEC50 values for respective
concentration-response curves are presented in Table 1.
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prevents organ culture-induced upregulation of contrac-
tile responses to 5-CT, Ang II, and ET-1. The effect on
receptor-mediated contraction was more prominent
after treatment with SB-590885, which is to be expected
because it has a lower Kd value, and therefore a higher
affinity for its ligand, than SB-380623 [12,13].
In vitro pharmacology
The maximum contraction elicited by 5-CT was signifi-
cantly reduced, as demonstrated by the reduction in
Emax after co-incubation with SB-590885 (Figure 1A,
Table 1). The receptor responsible for this contraction
has been demonstrated to be the 5-HT1B receptor sub-
type, which is also selectively expressed in human cere-
bral arteries, as demonstrated by protein 5-HT1B
expression and inhibition by a selective 5-HT1B antago-
nist [17-19]. The role of 5-HT and its receptors in
ischemia are not clear; while some studies report a pro-
tective role for 5-HT receptor agonists [20], others show
increased contractility and improvement with 5-HT
receptor antagonists [21]. Guilbert et al. show that 5-
HT1B is responsible for the 5-HT aggravation seen in
exercise-induced cardiac ischemia in dogs [21]. Addi-
tionally, 5-HT1B receptors have been suggested to inter-
act with 20-hydroxyeiscosatetraenoic acid (20-HETE)
and thereby contribute to the acute fall in regional cere-
bral blood flow after SAH [22]. We have previously
reported on increased 5-HT1B protein expression and
receptor-mediated contraction after SAH and organ cul-
ture in cerebral arteries [14,23], which could impair the
cerebral blood flow and thereby contribute to ischemic
damage. The present study demonstrates that the selec-
tive B-Raf inhibitor SB-590885 significantly decreases 5-
HT1B receptor-mediated vasoconstriction, suggesting
that the elevated contractile response of 5-HT1B recep-
tors observed after organ culture is regulated by the B-
Raf/MEK/ERK pathway.
Organ culture of isolated human arteries in the pre-
sence of SB-590885 or SB-386023 reduced Ang II-
mediated contraction (P < 0.001 for SB-590885 treated
vessels, Figure 1B, Table 1). Available data show that
cerebral vasoconstriction in response to Ang II is
mediated by AT1 receptors, while vasodilatation is
mediated by AT2 receptors [24]. The smooth muscle
cell AT1 receptors are upregulated and show enhanced
contractile responses after experimental cerebral ische-
mia [25] or in human ischemic stroke [5]. In support,
the reduced vasoconstrictor responses observed in the
present study after treatment with the B-Raf inhibitor
SB-590885 lead to a concomitant reduction of the AT1
receptor protein when examined immunohistochemi-
cally. The receptor identity has been confirmed using
selective antagonists for the AT2 receptor in human
brain vessels [15]. Blockade of the AT1 receptor has
been shown to improve injury after transient cerebral
ischemia [26,27] and to reduce cardiovascular morbidity
and mortality in stroke patients [28].
In agreement with a previous study, the selective ETB
receptor agonist sarafotoxin 6c (S6c) did not elicit any
vasoconstrictor responses in cultured human cerebral
arteries [16]. Therefore, the high-affinity phase of the
ET-1 biphasic concentration-response curve, corre-
sponding to ETB receptor-mediated contraction, was
studied. The same situation was seen in the rat middle
cerebral artery after experimental SAH, detailed phar-
macological analysis revealed participation of the ETB
receptor [29]. In the present study, we demonstrate a
Figure 2 The effect of organ culture and in vitro pharmacology experiments on hematoxylin-eosin staining in human cerebral vessel
sections. (A) Fresh, non-cultured vessel; (B) Vehicle-cultured vessel followed by in vitro pharmacology experiment. No morphological changes
were observed in the smooth muscle cell layer after the organ culture and in vitro pharmacology experiments compared with the fresh vessel
sections. Two compressed areas from the wires during the in vitro pharmacology experiments were observed (*). These areas were not used for
evaluation or analysis. Data were obtained with light microscopy. Insert: higher magnification, scale bar 50 μm.
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after co-incubation with SB-590885; SB-386023 had a
weaker effect (Figure 1C, Table 1). No effect on the ETA
receptor-mediated contraction was observed after treat-
ment with B-Raf inhibitors. It is well known that cere-
bral vessels have contractile ETA receptors in the
smooth muscle cells and relaxant ETB receptors in the
endothelium. However, there is a phenotypic change
after stroke in both animals and humans, with the
appearance of contractile ETB receptors in the smooth
muscle cells [5,30]. The effect of selective ETA blockers
on infarct volume after experimental stroke is ambigu-
ous, with studies showing both effect and no effect [2].
Results have been similar for the combined ETA and
ETB antagonists bosentan and clazosentan. One study
using an ETB blocker showed an increase in infarct
volume [31]. The administration of an ETB blocker in
conjunction with cerebral ischemia causes a blockade of
ETB receptor-mediated dilation, which exacerbates the
initial vasoconstriction and increases the infarct. The
ETB blocker might be beneficial if it is administered
after upregulation of the ETB receptor.
Figure 3 Human cerebrovascular receptor expression. (A) Double staining with actin shows expression of angiotensin II type 1 (AT1)
receptors in the medial layer. (B) AT1 receptor expression in fresh and in cultured vessel segments in the presence of vehicle, SB-590885, or SB-
386023. The increase in AT1 receptor immunoreactivity after culture was diminished significantly after treatment with SB-590885, and diminished
slightly after treatment with SB-386023. (C) No difference in endothelin type A (ETA) receptor expression was observed. Autofluorescence was
observed in internal elastic lamina. Data were obtained with epifluorescence microscopy. MED - medial layer, ADV - adventitial layer, and IEL -
internal elastic lamina.
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improving cerebral perfusion after ischemia because of
the opposing effects of a strong contractile ETA receptor
and a dilatory ETB receptor. However, a different
approach, whereby the signal transduction of the Raf/
MEK/ERK pathway was blocked with the MEK1/2 inhibi-
tor U0126, diminished the upregulated ETB receptor-
mediated contraction and reduced stroke volume [7].
Organ culture of rodent and human cerebral arteries is a
way to simulate ETB receptor upregulation and to study
the molecular mechanisms involved. In the present
study, we show that blockade of the MEK/ERK1/2 path-
way using upstream B-Raf inhibitors results in attenuated
ETB receptor-mediated contraction after organ culture.
Immunohistochemistry
When examined with hematoxylin-eosin staining, no
morphological changes were observed in the vessels
except for the regions where the steel wires used in the
in vitro pharmacology experiments have been attached
(Figure 2). However, it became obvious in the immuno-
histochemical examination that the vessels showed con-
siderable inter-individual differences, most likely due to
differences between the patients themselves. Some of
the patients exhibited more consistent results than
others (e.g., repeated immunostainings displayed stable
results). These inter-individual differences could explain
the inconsistency in the results obtained with the fluor-
escence intensity measurements.
Immunohistochemical staining using the 5-HT1B antibody
showed no differences between the groups. In other studies,
5-HT1B expression in rat cerebral arteries is increased after
middle cerebral artery occlusion and SAH [3,4].
AT1 receptor immunoreactivity was reduced after
treatment with SB-590885. Previously, increased AT1
receptor immunofluorescence after SAH in rats has
been shown to be reduced after application of SB-
386023 [32]. In our study, we observed a decrease in
AT1 receptor immunofluorescence intensity after
application of SB-590885, but only a small decrease
after SB-386023 (Figure 3B), results that are in accor-
dance with the in vitro pharmacology experiments.
ETA receptor-mediated contractile responses were not
significantly altered by the two B-Raf inhibitors used in
the present study (Figure 1C). Immunohistochemical
examination disclosed the same pattern; no differences
were observed between the groups (Figure 3C).
There was an increase in p-B-Raf immunoreactivity
after organ culture and this effect could be reduced con-
siderably in the presence of SB-590885 and SB-380623
(Figure 4). Therefore, the activation of B-Raf protein
kinase could be blocked by the application of specific
antagonists. We suggest that B-Raf is important for the
phenotypic changes of GPCRs observed in the smooth
muscle cells of cerebral arteries after organ culture and
cerebral ischemia [2]. An interesting question is whether
B-Raf functions alone or in a heterodimer in this aspect.
T h e r ei se v i d e n c ef o rB - R a f / C-Raf heterodimerization
with highly increased kinase activity compared with the
respective homodimers or monomers [33]. Further stu-
dies are needed to elucidate whether heterodimerization
is important for the regulation of GPCRs in vascular
smooth muscle cells after ischemia and organ culture.
Conclusions
In conclusion, we show that selective inhibition of B-Raf
using SB-590885 significantly attenuates 5-HT1B,A T 1,
and ETB receptor-mediated contraction in human cere-
bral arteries. Therefore, we suggest that B-Raf is impor-
tant for the altered GPCR expression observed after
cerebral ischemia, and that specific blockage might be a
novel approach to reduce tissue damage after stroke.
Methods
Ethics
This study was approved by the Regional Ethical Review
Board in Lund, Sweden (LU-818-01) and has been per-
formed in accordance with the Declaration of Helsinki.
Figure 4 Phosphorylated B-Raf (p-B-Raf) expression in human cerebral vessels. Cultured vessel with vehicle only shows increased
immunoreactivity compared with fresh, non-cultured vessel. This effect was markedly reduced after treatment with SB-590885 and SB-386023.
Data were obtained with epifluorescence microscopy. Insert: higher magnification, scale bar 50 μm.
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Cerebral arteries were obtained from patients undergoing
neurological surgery for removal of brain tumor or sei-
zure-producing cortex in severe cases of epilepsy (n = 7,
55 to 77 years old, 4 men and 3 women). Adjacent tissue
that was removed contained one or two vessel segments
that were used for the experiments. The vessels were dis-
sected during surgery and immediately immersed in cold,
sterile Dulbecco’s modified Eagle’s medium (DMEM,
Gibco, Invitrogen, Carlsbad, CA, USA) and transported
to the laboratory. The arteries were dissected free from
adhering tissue and cut into cylindrical segments
approximately 2 mm in length. The outer diameter of the
vessels ranged from 250 to 950 μm.
Organ culture
Arterial segments were cultured for 48 h at 37°C in humi-
dified 5% CO2 and air in serum-free DMEM supplemented
with penicillin (100 U/ml), streptomycin (100 μg/ml), and
amphotericin B (0.25 μg/ml) (Gibco). The method of blood
vessel culture and upregulation of contractile receptors has
been described previously [34]; the upregulation is not
altered with serum present in the medium or by incubation
in buffer only, but is a metabolically active process. The
segments were cultured in well plates, one segment per
well, in the absence or presence of B-Raf inhibitors: SB-
386023, 1 μM( K d B-Raf: 2.4 nM, GlaxoSmithKline, UK);
SB-590885, 1 μM, (Kd B-Raf: 0.3 nM, GlaxoSmithKline); or
the same volume of vehicle (dimethyl sulfoxide). Incuba-
tion was also performed with 10 μM SB-590885, which
resulted in non-viable arteries when examined by in vitro
pharmacology; therefore arteries incubated in SB-590855
were not used for further experiments. After 24 h of cul-
ture, the DMEM was replaced with new fresh medium and
inhibitors or vehicle were added as described above. For
each patient and group, one to three vessel segments were
incubated and examined by in vitro pharmacology and/or
immunohistochemistry (see below).
In vitro pharmacology
For contractile experiments, a myograph was used to
record the isometric tension in isolated cerebral arteries
[35,36]. The cylindrical segments were threaded on two
parallel stainless steel wires (diameter, 40 μm) and
mounted in a Mulvany-Halpern myograph (Danish Myo
Technology A/S, Aarhus, Denmark). One wire was con-
nected to a force displacement transducer attached to
an analogue-digital converter unit (ADInstruments,
Chalgrove, UK). The other wire was connected to a
micrometer screw, allowing adjustments of the distance
between the wires and therefore the vascular tone. Mea-
surements were recorded on a computer by use of a
Power Lab unit (ADInstruments). The vessel segments
were immersed in temperature-controlled tissue baths
(37°C) containing a bicarbonate buffer solution of the
following composition (mM): NaCl 119, NaHCO3 15,
KCl 4.6, MgCl2 1.2, NaH2PO4 1.2, CaCl2 1.5, and glu-
cose 5.6. The buffer was continuously aerated with oxy-
gen enriched with 5% CO2, resulting in pH 7.4. After an
equilibration period of ~20 min, each vessel segment
was stretched to 90% of the normal internal circumfer-
ence, which would be the size each vessel would have if
relaxed and under a transmural pressure of 100 mm Hg
[36]. The normalization procedure makes certain that all
vessel segments are set to a normalized internal circum-
ference giving maximal response. Subsequently, the ves-
sels were allowed to stabilize for 20-30 min. The
contractile capacity of the vessels was determined by
exposure to an isotonic solution containing 63.5 mM K
+, obtained by partial change of NaCl for KCl in the
above buffer. The contraction induced by K
+ was used
as reference for contractile capacity [35].
Concentration-response curves were obtained by
cumulative application of 5-CT (5-HT1B receptor ago-
nist, concentration range 10
-11 to 3·10
-5 M, Sigma, St.
Louis, USA), Ang II (AT1 and AT2 receptor agonist,
concentration range 10
-12 to 10
-6 M, Sigma) and ET-1
(ETA and ETB receptor agonist, concentration range 10
-
14 to 3·10
-7 M, Alexis Biochemicals, Farmingdale, NY,
USA). The contractile responses to S6c, a selective ETB
receptor agonist, were tested in a few samples and no
contractile responses were observed, in agreement with
a previous study [16]. Therefore, the high-affinity phase
of the ET-1 concentration-response curve was used to
study ETB receptor-mediated contraction.
Immunohistochemistry
Immediately after the in vitro pharmacology experi-
ments, the arterial segments were carefully dismantled
(n = 4) and embedded in Tissue TEK (Gibco), frozen on
dry ice, and kept at -80°C until cryosectioning (10 μm).
Additionally, both fresh (non-cultured) and cultured
arterial segments (described above) were directly
embedded in Tissue TEK without prior in vitro pharma-
cology experiments (n = 3). These arterial segments
were used for the ETA and ETB immunohistochemistry
experiments because of the irreversible binding of ET-1
to receptors in the in vitro pharmacology experiments
that would likely affect antibody-antigen binding [37].
The sections were collected onto Superfrost(r)Plus
(Menzel-Gläser, Braunschweig, Germany) glass slides
and stored at -80°C until immunohistochemistry. Sec-
tions from the in vitro pharmacology experiments were
stained with hematoxylin-eosin to evaluate vessel mor-
phology and the possible effects of the in vitro pharma-
cology experiments. Thawed sections were fixed for 10
minutes in -20°C acetone and rehydrated in phosphate
buffered saline (PBS, pH 7.2) containing 0.25% Triton X-
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tions were then blocked for 1 h at room temperature in
blocking solution containing PBS and 5% normal serum
(goat or donkey serum, depending on the secondary anti-
body hosts) to ensure secondary antibody specificity. Sub-
sequently, sections were incubated overnight at 4°C with
primary antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA, USA): goat anti-human 5-HT1B 1:100, rabbit
anti-human AT1 1:100, rabbit anti-human AT2 1:100, goat
anti-human ETB 1:150, and rabbit anti-human ETA 1:50,
diluted in PBST containing 1% bovine serum albumin
(BSA) and 3% normal serum. Following primary antibody
incubation, sections were rinsed in PBS for 2 × 15 min
and incubated for 1 h at room temperature with secondary
antibodies (FITC-conjugated goat anti-rabbit (Cayman
Chemical Co., Ann Arbor, MI, USA) 1:100 or Cy2-conju-
gated donkey anti-goat (Jackson ImmunoResearch, West
Grove, PA, USA) 1:200) in PBST containing 1% BSA and
3% normal serum (goat and donkey serum, respectively).
Sections were then rinsed in PBS for 2 × 15 min and
mounted in anti-fading mounting medium (Vectashield;
Vector Laboratories Inc., Burlingame, CA, USA) or polyvi-
nyl alcohol mounting medium (compatible with Cy2-con-
jugated secondary antibodies, Sigma). The procedure was
repeated on three different occasions to ensure reproduci-
bility. The same experimental procedure was used for
negative controls, but primary antibodies were omitted,
resulting in no staining in the tissue except for auto-fluor-
escence in the internal elastic lamina.
Double immunostaining was performed for the 5-
HT1B,A T 1,a n dE T B receptors. Antisera against the
receptors (described above) were used along with mouse
anti-human smooth muscle actin 1:200 (Santa Cruz Bio-
technology) and Texas Red-conjugated donkey anti-
mouse 1:200 (Jackson ImmunoResearch).
In addition, immunostaining against p-B-Raf was per-
formed on the sections. The protocol mentioned above
was used with a primary rabbit anti-human phosphospe-
cific B-Raf antibody 1:25 (Abcam, Cambridge, UK). The
secondary antibody used was Cy3-conjugated donkey
anti-rabbit 1:400 (Jackson ImmunoResearch).
Immunoreactivity was visualized at the appropriate
wavelengths with a light and epifluorescence microscope
(Nikon 80i; Tokyo, Japan) and photographed with an
attached Nikon DS-2Mv camera. To evaluate colocaliza-
tion, images from double immunostaining were super-
imposed in Adobe Photoshop CS (Adobe systems,
Mountain View, CA, USA).
Analysis and statistics
Contractile responses from the in vitro pharmacology
experiments are expressed as percentage of the contrac-
tion induced by 63.5 mM K
+. The Emax value represents
the maximum contractile response elicited by an agonist
and the pEC50 represents the negative logarithm of the
drug concentration that elicited half the maximum
response. For biphasic responses, Emax (1) and pEC50 (1)
describe the high-affinity phase, and Emax (2) and pEC50
(2) describe the low-affinity phase.
The protein expression of the 5-HT1B,A T 1,A T 2,E T B,
and ETA receptors in the smooth muscle cell layer of each
vessel were analyzed by fluorescence intensity measurements
in four areas within each vessel sample (n = 3 to 4 patients
in each group) by use of the ImageJ software http://rsb.info.
nih.gov/ij. The four areas were chosen after evaluating the
hematoxylin/eosin staining results of all specimens.
Data are expressed as mean ± standard error of the
mean (s.e.m.), and n refers to the number of patients.
Statistical analyses were performed with Kruskal-Wallis
non-parametric test followed by Dunn’sm u l t i p l ec o m -
parison test, where P < 0.05 was considered significant.
Study limitations
Human tissue was obtained during neurosurgery for
treatment of tumors or epilepsy. Although the surgeons
carefully dissected out adjacent non-cancerous or sei-
zure-producing tissue, effects on adjacent tissue cannot
be excluded. The collection of human cerebral arteries
is performed over a long period of time. Finally, there
was great variation in vessel diameter, owing to limited
access to human material.
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